We can’t show the full text here under this license. Use the link below to read it at the source.
Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors
Genetic changes and selective drugs that reduce β-arrestin increase cAMP signals at glucagon-related receptors
AI simplified
Abstract
GLP-1, GIP, and GCGR agonists with reduced β-arrestin-2 recruitment may improve insulin secretion.
- GLP-1R, GIPR, and GCGR regulate insulin secretion and energy metabolism.
- Reducing β-arrestin-2 recruitment in GLP-1R agonists has led to promising results in previous studies.
- In cells lacking both β-arrestin isoforms, cAMP/PKA signaling duration increased in response to the receptors' endogenous ligands.
- Biased GLP-1, GCG, and GIP analogs showed reduced receptor endocytosis and increased insulin secretion at high concentrations.
- Biased GCG analogs prolonged cAMP signaling duration without increasing glucose output from liver cells.
- Further research is required to optimize agonists targeting GLP-1R, GIPR, and GCGR for therapeutic applications.
AI simplified